Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.63 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29423393 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29493550 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL2558967 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL15480253 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL8904188 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29415589 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL16401903 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL2558970 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL22283176 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL23138547 | 0.94 | CASP3 (0.58) | CASP3MDM4TP53KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351780-B2 | Peptide acetals for stabilising enzymes | BASF SE (DE) | 2025-07-08 | — | — | US | claimed |
| US-20220267699-A1 | PEPTIDE ACETALS FOR STABILISING ENZYMES | BASF SE (DE) | 2022-08-25 | — | — | US | claimed |
| EP-3994148-A1 | PEPTIDE ACETALS FOR STABILISING ENZYMES | BASF SE (DE) | 2022-05-11 | — | — | EP | claimed |
| EP-4735047-A1 | PEGYLATED LINKERS AND USES THEREOF | Université de Tours (FR) | 2026-05-06 | — | — | EP | disclosed |
| US-12576158-B2 | Antibody drug conjugates with cleavable linkers | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2026-03-17 | — | — | US | disclosed |
| US-12514926-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-01-06 | — | — | US | disclosed |
| US-20250135017-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-05-01 | — | — | US | disclosed |
| WO-2025078841-A2 | ANTIBODIES, CONJUGATES, AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| CN-119630672-A | Camptothecin derivative and conjugate thereof, and preparation method and medical application thereof | 一线医药（杭州）有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119405834-A | Splice modulating antibody-drug conjugates and methods of use thereof | 卫材R&D管理有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119405831-A | Splice modulating antibody-drug conjugates and methods of use thereof | 卫材R&D管理有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20230116913-A2 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2023-04-13 | — | — | US | disclosed |
| US-20220380352-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2022-12-01 | — | — | US | disclosed |
| US-20220339287-A9 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2022-10-27 | — | — | US | disclosed |
| US-11352348-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| CN-114585636-A | Preparation method of procatide | 深圳市健元医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-108349960-B | Nostoc compounds and conjugates, their preparation and their therapeutic use | 赛诺菲 | 2022-05-27 | — | — | CN | disclosed |
| CN-108093640-B | Site-specific antibody-drug conjugates | ADC治疗股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-3972648-A1 | ANTIBODY DRUG CONJUGATES WITH CLEAVABLE LINKERS | Heidelberg Pharma Research GmbH (DE) | 2022-03-30 | — | — | EP | disclosed |
| CN-114144201-A | Antibody drug conjugates containing a cleavable linker | 海德堡医药研究有限责任公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267699-A1 | PEPTIDE ACETALS FOR STABILISING ENZYMES | IDE, PEPD, PREP | CASP3 2668/4885MDM4 2438/4885TP53 2731/4885 |
| US-12351780-B2 | Peptide acetals for stabilising enzymes | IDE, PEPD, PREP | CASP3 2668/4885MDM4 2438/4885TP53 2731/4885 |
| US-11352348-B2 | Splicing modulator antibody-drug conjugates and methods of use | RBM17, RBM22, SF3B1 | CASP3 2138/4885MDM4 2116/4885TP53 582/4885 |
| US-20220380352-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | RBM17, RBM22, SF3B1 | CASP3 2138/4885MDM4 2116/4885TP53 582/4885 |
| US-12576158-B2 | Antibody drug conjugates with cleavable linkers | PTMS, C3AR1, ANPEP | CASP3 168/4885MDM4 3831/4885TP53 394/4885 |
| US-20250135017-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | RBM17, SNRPE, HNRNPAB | CASP3 3597/4885MDM4 2300/4885TP53 720/4885 |
| US-20220339287-A9 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | STING1, CGAS, TLR9 | CASP3 2167/4885MDM4 1835/4885TP53 1308/4885 |
| US-20230116913-A2 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | STING1, CGAS, TLR9 | CASP3 2167/4885MDM4 1835/4885TP53 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.